Johnson & Johnson Completes Acquisition of V-Wave

October 9, 2024—Johnson & Johnson announced the completion of its acquisition of V-Wave Ltd., a privately held company focused on developing treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech.

According to the company, the acquisition of V-Wave extends Johnson & Johnson MedTech’s position in cardiovascular disease, complementing its portfolio of platforms that address coronary artery disease, peripheral artery disease, heart recovery, and atrial fibrillation. It will also deepen the company’s relationships with structural interventional cardiologists and heart failure specialists.

Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, commented in the press release, “We’re excited to officially welcome V-Wave to Johnson & Johnson MedTech. V-Wave’s novel implantable device, the Ventura interatrial shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction. This technology has the potential to be the first device of its kind to market. We look forward to working with the talented V-Wave team to bring this transformative innovation to patients.”

On August 20, 2024, the company announced the definitive agreement to acquire V-Wave. That press release advised that under the terms of the agreement, the acquisition included an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.